Back to School: How biopharma can reboot drug development. Access exclusive analysis here

REGN in oral Axokine deal with EMIS

The companies will use Emisphere's oral drug delivery technology

Read the full 92 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE